Biomarkers to guide anticoagulation | |
---|---|
CDC | Insufficient data to recommend for or against using hematologic and coagulation parameters to guide management decisions. |
ISTH-IG | Not mentioned |
ACF | Biomarker thresholds such as D-dimer for guiding anticoagulation management should not be done outside the setting of a clinical trial. |
ASH | No particular change to regimen recommended for patients with lupus like inhibitors. TEG and ROTEM should not be used routinely to guide management. |
ACCP | Not mentioned |
SSC-ISTH | D-dimer levels should not be used solely to guide anticoagulation regimens. |
ACC | Further investigation is required to determine the role of antiphospholipid antibodies in pathophysiology of COVID-19-associated thrombosis. D-dimer > 2 times the upper limit may suggest that patient is at high risk for VTE and consideration of extended prophylaxis (up to 45 days) in patients at low risk of bleeding. |